[Correlation between metabolic syndrome and clinical progression in patients with benign prostatic hyperplasia]

To assess the correlation between metabolic syndrome and clinical progression in patients with benign prostatic hyperplasia (BPH).

A total of 382 BPH patients with lower urinary tract symptoms were divided into two groups according to whether or not there was a diagnosis of metabolic syndrome (MS). MS was defined by the International Diabetes Federation (IDF) in 2005. Abdominal B-ultrasound was used to measure the total volume of prostate (TP) and its average annual growth rate was calculated. Body mass index, waist-hip ratio, blood biochemistry, blood pressure, blood glucose and other indicators were compared in these two groups of patients with regards to the clinical progression associated with BPH.

A total of 187 MS cases were found in 382 (48.59%) BPH patients. It showed a higher body mass index, high glycemia, high triglycerides, high blood pressure and high IPSS, TP and PSA levels. Also it showed a higher occurrence of surgical rate (P < 0.05); its average annual growth rate of TP was significantly higher than those without MS (1.0 vs 0.64 ml/yr, P < 0.05). TP average annual growth rate and IPSS score are found significantly correlated with blood glucose and triglyceride levels (P < 0.01).

Metabolic syndrome affects the clinical progression in patients with BPH. Clinical attention should be paid.